ASX Announcement: MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to report
Imagion to present prostate cancer research data at World Molecular Imaging Congress MagSense® molecular imaging agent shows high specificity and selectivity MELBOURNE — Imagion Biosystems
Today, we released our Appendix 4D and Half-Year Financial Report for the half-year ending 30 June 2022 to the ASX. 1H2022 Highlights: MagSense® HER2 breast
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 30 June 2022. The announcement highlights: MagSense® HER2 imaging agent
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast cancer
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the
The document “Application for quotation of +securities” was lodged with ASX on 6th January, 2022. Please click to review the full announcement at ASX.
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 6th January, 2022. Please click to review the
The document “Notification of Issue, Conversion of Payment up of Unquoted Equity +Securities” was lodged with ASX on 16 December, 2021. Please click to review
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance
